Zalcitabine

This drug is used cautiously in patients with peripheral vascular disease, neuropathy, chronic pancreatitis, or impaired liver function. Didanosine is a Pregnancy Category B drug and is used cautiously during pregnancy and lactation. There may be a decrease in the effectiveness of dapsone in preventing Pneumocystis carinii pneumonia when didanosine is administered with dapsone Use of didanosine with zalcitabine may cause additive neuropathy. Absorption of didanosine is decreased when it is administered with food. [Pg.124]

C2H3BrO 506-96-7) see Paclitaxel N-acetyl-2 -bromo-2 -deoxycytidine 3, S -diacetate (C 5HigBrN307 126430-12-4) see Zalcitabine A -acetyl-3 -bromo-3 -deoxycytidine 2, 5 -diacetate (C 5H gBrN307 126430-11-3) see Zalcitabine 2-acetyl-4-butyramidophenol (C 2H,5N03 40188-45-2) see Acebutolol... [Pg.2283]

Ci jHijBrjNO 4614-45-3) see Oxcarbazepine 3-acetyl-2,5-dichlorothiophene (CSH4CI2OS 36157-40-1) see Brinzolamide A -acetyl-2, 3 -didehydro-2, 3 -dideoxycytidine S -acetate (CJ3H15N3O5 62805-52-1) see Zalcitabine... [Pg.2283]

At present there are seven NRTIs, which have been formally approved for the treatment of AIDS 3 -azido-2, 3 -dideoxythymidine (AZT, zidovudine), 2, 3 -dideoxyinosine (ddl, didanosine), 2, 3 -dideoxycytidine (ddC, zalcitabine), 2, 3 -didehydro-2, 3 -dideoxythymidine (d4T, stavudine), (—)-L-3 -thia-2, 3 -dideoxycytidine (3TC, lamivudine), cyclopentenyl V -cyclopropylaminopurine (abacavir, ABC), and (—)-L-5-fluoro-3 -thia-2, 3 -dideoxycytidine ((—)FTC, emtricitabine) (De Clercq 2004a) (Fig. 3). [Pg.73]

Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, Holden-Wiltse J, Meehan PM (1997) Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. J Acquit Immune Deflc Syndr Hum Retrovirol 16 247-253... [Pg.233]

NRTls are structural analogues of the natural nucleotides that form the building blocks of RNA and DNA in human cells. Their use as part of HAART has dramatically modified the natural history of HIV infection. They, however, cause a range of drag- or tissue-specific toxicides zidovudine (AZT) causes myopathy zalcitabine (ddC), didanosine (ddl), and lamivudine (3TC) cause neuropathy stavudine (d4T) causes neuropathy or myopathy and lactic acidosis (Dalakas 2001). During phase 1 and 11 trials, the dose-limiting toxicity of didanosine, zalcitabine, and stavudine was identified as peripheral neuropathy (Dalakas 2001). [Pg.71]

Blum AS, Dal Pan GJ et al (1996) Low-dose zalcitabine-related toxic neuropathy frequency, natural history, and risk factors. Neurology 46(4) 999-1003 Bradley WG, Verma A (1996) Painful vascuhtic neuropathy in HlV-1 infection relief of pain with prednisone therapy. Neurology 47(6) 1446-1451 Breen EC (2002) Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther 95(3) 295-304 Bremer J (1990) The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem 28(5) 297-301... [Pg.78]

Didanosine, 1-asparaginase, lamivudine, metformin, pentamidine, statins, stavudine, sulindac, valproic acid, and zalcitabine... [Pg.118]

Valproic acid/salts Losartan Meglumine antimoniate Piroxicam Procainamide Salicylates Sodium stibogluconate Zalcitabine... [Pg.338]

Drugs that should not be combined due to overlapping toxi-cities include amprenavir oral solution plus ritonavir oral solution, atazanavir plus indinavir (due to enhanced hyperbilirubinemia), and any combination of didanosine, stavudine, and zalcitabine. Emtricitabine and lamivudine should not be combined because of their similar chemical structures, and antagonism can result when lamivudine is combined with zalcitabine, or stavudine is combined with zidovudine. [Pg.1259]

Zalcitabine (ddC) Hivid (anticipated discontinuation of distribution in 2006) 0.375-, 0.75-mg tab 0.75 mg tid CrCI Dose (mL/minute) 10-40 0.75 mg bid less than 10 0.75 mg qday No data on hemodialysis None Peripheral neuropathy stomatitis, lactic acidosis with hepatic steatosis (rare but potentially life-threatening toxicity with use of NRTIs) pancreatitis Renal excretion... [Pg.1262]

APV, amprenavir ATV, atazanavir CNS, central nervous system CVD, cardiovascular disease D/C, discontinue ddC, zalcitabine ddl, didanosine DEXA, dual-energy x-ray absorptiometry d4T, stavudine EFV, efavirenz HDL, high-density lipoprotein HIV, human immunodeficiency virus HTN, hypertension IDV, indinavir LDL, low-density lipoprotein LPV/r, lopinavir+ ritonavir MRI, magnetic resonance imaging NNRTI, nonnucleoside reverse transcriptase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NVP, nevirapine PI, protease inhibitor RTV, ritonavir SQV, saquinavir TDF, tenofovir disoproxil fumarate TG, triglyceride TPV/r, tipranivir + ritonavir ZDV, zidovudine. [Pg.1273]

In addition to the three anti-HIV agents [AZT (zidovudine), DDI (dida-nosine) and DDC (zalcitabine)] that have been formally approved by the U.S. Food and Drug Administration for the treatment of HIV infections, several other 2, 3 -dideoxynucleoside (ddN) analogues (Fig. 5), including 3 -fluoro-2, 3 -didcoxy-5-chlorouridine (FddClUrd) and 2, 3 -didehydro-... [Pg.319]

See also in sourсe #XX -- [ Pg.62 , Pg.73 ]

See also in sourсe #XX -- [ Pg.504 ]

See also in sourсe #XX -- [ Pg.288 ]

See also in sourсe #XX -- [ Pg.407 ]

See also in sourсe #XX -- [ Pg.1312 ]

See also in sourсe #XX -- [ Pg.554 ]

See also in sourсe #XX -- [ Pg.352 ]

See also in sourсe #XX -- [ Pg.179 ]

See also in sourсe #XX -- [ Pg.531 , Pg.537 ]

See also in sourсe #XX -- [ Pg.140 , Pg.140 ]

See also in sourсe #XX -- [ Pg.363 , Pg.369 , Pg.370 , Pg.370 ]

See also in sourсe #XX -- [ Pg.290 ]

See also in sourсe #XX -- [ Pg.5 , Pg.9 ]

See also in sourсe #XX -- [ Pg.325 ]

See also in sourсe #XX -- [ Pg.206 ]

See also in sourсe #XX -- [ Pg.260 ]

See also in sourсe #XX -- [ Pg.1269 , Pg.2315 ]

See also in sourсe #XX -- [ Pg.44 , Pg.285 , Pg.320 ]

See also in sourсe #XX -- [ Pg.396 ]

See also in sourсe #XX -- [ Pg.253 , Pg.254 ]

See also in sourсe #XX -- [ Pg.87 , Pg.675 , Pg.740 ]

See also in sourсe #XX -- [ Pg.431 , Pg.434 ]

See also in sourсe #XX -- [ Pg.1215 , Pg.1216 ]

See also in sourсe #XX -- [ Pg.319 ]

See also in sourсe #XX -- [ Pg.396 ]

See also in sourсe #XX -- [ Pg.116 ]

See also in sourсe #XX -- [ Pg.545 ]

See also in sourсe #XX -- [ Pg.2 , Pg.335 , Pg.336 ]

See also in sourсe #XX -- [ Pg.203 ]

See also in sourсe #XX -- [ Pg.202 ]

See also in sourсe #XX -- [ Pg.479 , Pg.480 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...